Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,141 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo: Group 4 - Placebo Clear all
Completed Phase 2 Interventional

Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients

NCT00082498
View directory record Official record
Conditions
HIV Infections
Interventions
SCH-D (vicriviroc), Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
30
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

EXPAREL for Minimally Invasive Supracervical Hysterectomies

NCT03769714
View directory record Official record
Conditions
Pain
Interventions
Saline Solution for Injection, Exparel
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism

NCT00872898
View directory record Official record
Conditions
Autism
Interventions
Memantine - Extended Release (ER), Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
17
States / cities
Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Vabicaserin in Subjects With Schizophrenia

NCT00563706
View directory record Official record
Conditions
Schizophrenia
Interventions
vabicaserin, risperidone, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Little Rock, Arkansas • Cerritos, California • Escondido, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Sep 17, 2026, 3:06 AM EDT
Recruiting Phase 3 Interventional

SMART Exercise for PAD

NCT06032065
View directory record Official record
Conditions
Peripheral Arterial Disease, Aging, Peripheral Vascular Diseases, Walking, Difficulty
Interventions
Supervised Treadmill Exercise, Home-Based Exercise, Nitrate-rich beetroot Juice
Behavioral · Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Chicago, Illinois • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

NCT03207243
View directory record Official record
Conditions
Asthma
Interventions
GSK3772847, Placebo, Fluticasone propionate/salmeterol, Fluticasone propionate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsboro, Alabama • Bakersfield, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2 Interventional

7-Keto DHEA for the Treatment of PTSD

NCT01861847
View directory record Official record
Conditions
PTSD
Interventions
7-Keto Dehydroepiandrosterone, Placebo
Drug
Lead sponsor
Humanetics Corporation
Industry
Eligibility
18 Years to 64 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bay Pines, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 17, 2026, 3:06 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05287113
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Retifanlimab, INCAGN02385, INCAGN02390, Placebo
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years to 99 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Scottsdale, Arizona • Duarte, California • Irvine, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis

NCT00550043
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
INCB018424, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Huntsville, Alabama • Upland, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

NCT00385697
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Teplizumab, Placebo
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
8 Years to 35 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
39
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2 Interventional

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

NCT01688947
View directory record Official record
Conditions
Postherpetic Neuralgia, Pain
Interventions
V116517 50-mg tablets, V116517 30-mg tablets, Pregabalin capsules, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
21 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
28
States / cities
Tucson, Arizona • La Jolla, California • North Hollywood, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 17, 2026, 3:06 AM EDT
Active, not recruiting Not applicable Interventional

ViDES Trial (Vitamin D Extra Supplementation)

NCT05459298
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Placebo, 800 IU/day vitamin D supplementation with feedings in the first 28 days after birth, Usual Care
Dietary Supplement · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
24 Hours to 96 Hours
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

NCT07703514
View directory record Official record
Conditions
Influenza
Interventions
cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)

NCT02527798
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Furosemide Cohort 1, Furosemide Cohort 2, Furosemide Cohort 3, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
7 Days to 28 Days
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
21
States / cities
Little Rock, Arkansas • Loma Linda, California • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

NCT00571649
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Rivaroxaban placebo, Enoxaparin placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
8,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
121
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 1 Interventional

Growth Hormone Administration and the Human Immune System

NCT00663611
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Norditropin, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
25 Years to 50 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Terminated Phase 2 Interventional Results available

Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03616821
View directory record Official record
Conditions
Ulcerative Colitis, IBD
Interventions
Brazikumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

ACEs, SIRT1, and Premature Vascular Aging in Humans

NCT07073352
View directory record Official record
Conditions
Adverse Childhood Experiences, Endothelial Dysfunction
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

NCT03090100
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo, Secukinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Oceanside, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dose-Response of Gonadal Steroids and Bone Turnover in Older Men

NCT00114114
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Testosterone, Goserelin acetate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 75 Years · Male only
Enrollment
177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Glutathione and Fuel Oxidation in Aging

NCT01870193
View directory record Official record
Conditions
Aging
Interventions
Glycine, cysteine (as n-acetylcysteine), alanine
Dietary Supplement
Lead sponsor
Rajagopal V Sekhar
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Methylphenidate and a Nursing Telephone Intervention for Fatigue

NCT00424099
View directory record Official record
Conditions
Advanced Cancer, Fatigue
Interventions
Methylphenidate, Nursing Telephone Intervention, Placebo, Non NTI
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 3 Interventional

Acupuncture for Post-Thoracotomy Pain

NCT00142532
View directory record Official record
Conditions
Lung Cancer, Pain
Interventions
Acupuncture and Questionnaires, Placebo Acupuncture, Questionnaires
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2009 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CP-481,715 Nickel Allergy Study.

NCT00141180
View directory record Official record
Conditions
Dermatitis, Allergic Contact
Interventions
CP-481,715
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
4
States / cities
Ann Arbor, Michigan • New York, New York • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2006 · Synced Sep 17, 2026, 3:06 AM EDT